| 07/22/2026 4:19 PM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/22/2026 4:21 PM | Dyne Therapeutics (1818794) Filer | Form 424B5 | |
| 07/21/2026 4:22 PM | Dyne Therapeutics (1818794) Filer | Form 424B5 | |
| 07/20/2026 6:35 AM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/08/2026 4:35 PM | Dyne Therapeutics (1818794) Issuer Rhodes Jason P (1577014) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/07/2026 4:05 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/07/2026 4:05 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/07/2026 4:06 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/07/2026 4:06 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/06/2026 4:17 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/06/2026 4:17 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
Get the Latest News and Ratings for DYN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 07/06/2026 4:17 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/30/2026 6:05 PM | Dyne Therapeutics (1818794) Issuer Rhodes Jason P (1577014) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/29/2026 4:49 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/29/2026 4:50 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/29/2026 4:50 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/26/2026 4:04 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/26/2026 4:04 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/26/2026 4:04 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/26/2026 7:40 AM | Dyne Therapeutics (1818794) Issuer Rhodes Jason P (1577014) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/25/2026 4:28 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/25/2026 4:29 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/25/2026 4:29 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/25/2026 4:11 PM | Dyne Therapeutics (1818794) Subject Lucera Erick (1697616) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/24/2026 4:32 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/24/2026 4:33 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/24/2026 4:36 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/24/2026 3:27 PM | Dyne Therapeutics (1818794) Issuer Kersten Dirk (1823682) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/23/2026 5:25 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/23/2026 5:26 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/23/2026 5:19 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/23/2026 3:05 PM | Dyne Therapeutics (1818794) Issuer Greene Barry E (1291963) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 06/23/2026 3:07 PM | Dyne Therapeutics (1818794) Issuer Greene Barry E (1291963) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/22/2026 3:15 PM | Dyne Therapeutics (1818794) Issuer Kersten Dirk (1823682) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/22/2026 3:15 PM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/17/2026 3:03 PM | Dyne Therapeutics (1818794) Subject ForDyne B.V. (2019392) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/17/2026 3:07 PM | Cox John (1498428) Reporting Dyne Therapeutics (1818794) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/17/2026 6:35 AM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/09/2026 4:09 PM | Dyne Therapeutics (1818794) Issuer Stehman-Breen Catherine (1702233) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2026 4:12 PM | Dyne Therapeutics (1818794) Issuer Incerti Carlo (1915358) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2026 4:12 PM | Dyne Therapeutics (1818794) Issuer Kersten Dirk (1823682) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
ALERT: Drop these 5 stocks before the market opens tomorrow! (Ad) The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings.
Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds.
If any of these are in your portfolio, now is the time to review your positions. See the 5 stocks to avoid |
| 06/09/2026 4:13 PM | Dyne Therapeutics (1818794) Issuer Rhodes Jason P (1577014) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2026 4:13 PM | Dyne Therapeutics (1818794) Issuer Lubner David Charles (1572000) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2026 4:15 PM | Dyne Therapeutics (1818794) Issuer HURWITZ EDWARD (1211840) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2026 4:06 PM | Dyne Therapeutics (1818794) Issuer Posner Brian S (1372455) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/08/2026 3:05 PM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/03/2026 6:35 AM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/15/2026 11:36 AM | Dyne Therapeutics (1818794) Subject JANUS HENDERSON GROUP PLC (1274173) Filed by | Form SCHEDULE 13G/A | |
| 05/14/2026 3:04 PM | Dyne Therapeutics (1818794) Issuer Kerr Douglas (1814189) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/14/2026 3:05 PM | Dyne Therapeutics (1818794) Issuer Friedl-Naderer Johanna (1915598) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/13/2026 3:55 PM | Dyne Therapeutics (1818794) Subject Lucera Erick (1697616) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/13/2026 3:57 PM | Cox John (1498428) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/11/2026 6:25 AM | Dyne Therapeutics (1818794) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 05/11/2026 6:35 AM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/06/2026 4:09 PM | Dyne Therapeutics (1818794) Issuer Rhodes Jason P (1577014) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/06/2026 3:42 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/06/2026 3:42 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/06/2026 3:43 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/06/2026 10:13 AM | Dyne Therapeutics (1818794) Subject FMR LLC (315066) Filed by | Form SCHEDULE 13G | |
| 05/05/2026 3:36 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/05/2026 3:36 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/05/2026 3:37 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/04/2026 3:59 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/04/2026 3:59 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/04/2026 3:59 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/04/2026 4:00 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/30/2026 4:22 PM | Dyne Therapeutics (1818794) Issuer Rhodes Jason P (1577014) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/28/2026 3:56 PM | Dyne Therapeutics (1818794) Issuer Lubner David Charles (1572000) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/28/2026 3:42 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/28/2026 3:43 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/28/2026 3:43 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/28/2026 3:44 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 5:15 PM | Dyne Therapeutics (1818794) Issuer Rhodes Jason P (1577014) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/27/2026 3:48 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 3:48 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 3:48 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 3:49 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/24/2026 3:45 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/24/2026 3:46 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/24/2026 3:46 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/24/2026 3:47 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/23/2026 3:45 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/23/2026 3:45 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/23/2026 3:45 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/23/2026 3:46 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/23/2026 3:15 PM | Dyne Therapeutics (1818794) Filer | Form ARS | |
| 04/23/2026 3:15 PM | Dyne Therapeutics (1818794) Issuer Kersten Dirk (1823682) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/23/2026 3:05 PM | Dyne Therapeutics (1818794) Filer | Form DEF 14A | |
| 04/22/2026 5:27 PM | Dyne Therapeutics (1818794) Issuer Rhodes Jason P (1577014) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/22/2026 3:52 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/22/2026 3:53 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
The end may be near for these iconic stocks (Ad) Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge.
Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks.
Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. Watch Marc Chaikin's free presentation and get his full buy-and-sell list today |
| 04/22/2026 3:53 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/22/2026 3:54 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/21/2026 3:53 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/21/2026 3:53 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/21/2026 3:53 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/21/2026 3:54 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/21/2026 3:15 PM | Dyne Therapeutics (1818794) Issuer Kersten Dirk (1823682) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/20/2026 3:43 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/20/2026 3:44 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |